Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to
first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the
disease control of musculoskeletal lesions is worse than that of pulmonary lesions. This
treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE).
We have ever retrospectively compared the activity of apatinib + IE in relapsed or refractory
osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with
multiple sites of metastasis, apatinib + IE demonstrated clinically meaningful antitumor
activity and delayed disease progression in patients with recurrent or refractory
osteosarcoma after failure of chemotherapy. However to overcome the influence of other
interventions on the outcome, we are currently performing a prospective trial to investigate
this combination, from which more accurate data on this treatment strategy are expected.